/

Business

Field Trip FT-104 5-HO-DiPT

An Inside Look into Field Trip’s Next-Generation Psychedelic, FT-104

,
Field Trip is the only company exploring the therapeutic potential of a 4-HO-DiPT prodrug called FT-104. But how does it work?
Compass Pathways Sued

Compass Pathways Sued for Stealing Trade Secrets

,
Compass Pathways faces a legal challenge from Terran Biosciences over the potential theft of intellectual property
Cybin Entheon DMT Clinical TrialSutterstock

The Real Reason Cybin Bought Entheon’s DMT Clinical Trial

, ,
In a rare move Cybin aquires a phase 1 DMT clinical trial from Entheon Biomedical. CEO Doug Drysdale explains why in a Reddit AMA
TheraPsil Project Solace

Project Solace: The World’s Largest Medical Psilocybin Access and Data Project

,
Project Solace uses real-world data to inform development of regulated psilocybin therapy, led by Canadian non-profit TheraPsil
Microdosing clinical trialsSutterstock

3 Microdosing Clinical Trials to Keep an Eye On

,
Does microdosing psychedelics work, or is it the placebo effect? Here are 3 microdosing clinical trials looking for answers
Psychedelic Stocks Compass Small Pharma Mydecine Awakn

A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 Trial

,
Compass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research
NaturoMed Therapeutics

Company Spotlight: NaturoMed Therapeutics

Canadian organic mushroom company NaturoMed Therapeutics looks to produce psilocybin in Q4 2022
Compass Pathways Appoints a New CEO

Compass Pathways Appoints a New CEO

,
George Goldsmith will be replaced as Compass Pathways CEO. Is this good or bad news?

The Battle for Psychedelic Patents

,
Psychedelic companies rely on novel patents to boost their value, but many players in the space are chasing the same IP

© 2023 Psychedelic Spotlight. | Owned and operated by PSYC Media Corporation, Inc. a US publicly traded company (OTCPink: PSYC) | All Rights Reserved.